lobbying_activities: 1582052

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1582052	d63966d0-673e-4d77-ab6c-7da99e75d932	Q3	RED+BLUE STRATEGIES	400693064	EXPRESS SCRIPTS INC.	2014	third_quarter	PHA	H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy. Rules, regulations and guidance specific to prescription drug pricing, generic utilization, biosimilars and specialty pharmacy. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in naming policies for upcoming biosimilars. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefit. Issues regarding prescription drug coverage for public benefit programs. Issues related to Part D coverage for Medicare beneficiaries in hospice care.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2014-10-06T16:04:11.580000-04:00